451 related articles for article (PubMed ID: 17547502)
1. Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination.
Gin A; Dilay L; Karlowsky JA; Walkty A; Rubinstein E; Zhanel GG
Expert Rev Anti Infect Ther; 2007 Jun; 5(3):365-83. PubMed ID: 17547502
[TBL] [Abstract][Full Text] [Related]
2. Piperacillin-Tazobactam: a new beta-lactam-beta-lactamase inhibitor combination.
Daniel KP; Krop LC
Pharmacotherapy; 1996; 16(2):149-62. PubMed ID: 8820460
[TBL] [Abstract][Full Text] [Related]
3. Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.
Schoonover LL; Occhipinti DJ; Rodvold KA; Danziger LH
Ann Pharmacother; 1995 May; 29(5):501-14. PubMed ID: 7655135
[TBL] [Abstract][Full Text] [Related]
4. Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.
Perry CM; Markham A
Drugs; 1999 May; 57(5):805-43. PubMed ID: 10353303
[TBL] [Abstract][Full Text] [Related]
5. Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.
Young M; Plosker GL
Pharmacoeconomics; 2001; 19(11):1135-75. PubMed ID: 11735679
[TBL] [Abstract][Full Text] [Related]
6. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
Mohanty S; Singhal R; Sood S; Dhawan B; Das BK; Kapil A
Indian J Med Res; 2005 Nov; 122(5):425-8. PubMed ID: 16456257
[TBL] [Abstract][Full Text] [Related]
8. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
Cho JC; Fiorenza MA; Estrada SJ
Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
[TBL] [Abstract][Full Text] [Related]
9. Clinical use of beta-lactamase inhibitors in combination with extended-spectrum penicillins.
Jones RN
Am J Health Syst Pharm; 1995 Mar; 52(6 Suppl 2):S29-33. PubMed ID: 7606587
[TBL] [Abstract][Full Text] [Related]
10. Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
Bryson HM; Brogden RN
Drugs; 1994 Mar; 47(3):506-35. PubMed ID: 7514977
[TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
Sader HS; Tosin I; Sejas L; Miranda E
Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of piperacillin/tazobactam versus other broad-spectrum antibiotics against nosocomial gram-negative pathogens isolated from burn patients.
Mokaddas E; Rotimi VO; Sanyal SC
J Chemother; 1998 Jun; 10(3):208-14. PubMed ID: 9669645
[TBL] [Abstract][Full Text] [Related]
13. Activity of beta-lactam beta-lactamase inhibitor combinations against extended spectrum Beta-lactamase producing Enterobacteriaceae in urinary isolates.
Afridi FI; Farooqi BJ
J Coll Physicians Surg Pak; 2012 Jun; 22(6):358-62. PubMed ID: 22630093
[TBL] [Abstract][Full Text] [Related]
14. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam.
Peterson LR
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():181-4. PubMed ID: 18154544
[TBL] [Abstract][Full Text] [Related]
15. Review of piperacillin/tazobactam in the treatment of bacteremic infections and summary of clinical efficacy.
Charbonneau P
Intensive Care Med; 1994 Jul; 20 Suppl 3():S43-8. PubMed ID: 7962989
[TBL] [Abstract][Full Text] [Related]
16. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
[TBL] [Abstract][Full Text] [Related]
17. Occurrence of ESBL & Amp-C beta-lactamases & susceptibility to newer antimicrobial agents in complicated UTI.
Taneja N; Rao P; Arora J; Dogra A
Indian J Med Res; 2008 Jan; 127(1):85-8. PubMed ID: 18316858
[TBL] [Abstract][Full Text] [Related]
18. An observational study on the epidemiology of respiratory tract bacterial pathogens and their susceptibility to four injectable beta-lactam antibiotics: piperacillin, piperacillin/tazobactam, ceftazidime and ceftriaxone.
Varotto F; Maria GD; Azzaro R; Bellissima P; Amato R; Fogliani V; Muscianisi G; Vitale S; Girbino G; Andò F; Laganà P; Delia S; Jacoviello C; Maierna G; Pezza A; Covelli I; Magrì M; Napoletano G; Rossi A; Marone P; Sanguinetti C; Pela R; Tedeschi D; Viola B; Cicciarella S; Messina G; Rizza S; Fraschini F
J Chemother; 2001 Aug; 13(4):413-23. PubMed ID: 11589485
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of piperacillin/tazobactam in skin and soft tissue infections.
File TM; Tan JS
Eur J Surg Suppl; 1994; (573):51-5. PubMed ID: 7524796
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections.
Hou F; Li J; Gao L; Chen Y
Chin Med J (Engl); 1998 Nov; 111(11):1039-43. PubMed ID: 11189212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
